SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)

No safety concerns or dose limiting toxicities observedSCY-247 was able to achieve target exposures at doses lower than our first-generation ...